NASDAQ:CTSO Cytosorbents (CTSO) Stock Price, News & Analysis $5.75 -0.01 (-0.17%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$5.74 -0.01 (-0.10%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Cytosorbents Stock (NASDAQ:CTSO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cytosorbents alerts:Sign Up Key Stats Today's Range$5.50▼$6.0050-Day Range$5.73▼$8.0052-Week Range$5.13▼$20.40Volume11,771 shsAverage Volume25,695 shsMarket Capitalization$18.11 millionP/E RatioN/ADividend YieldN/APrice Target$107.50Consensus RatingHold Company Overview CytoSorbents Corporation develops medical devices and blood-purification technologies designed to remove harmful substances from the bloodstream. Its proprietary technology uses porous polymer adsorbent beads that can capture and reduce levels of inflammatory mediators, drugs, toxins and other compounds without selectively removing beneficial blood components. The company’s principal product, CytoSorb, is used in extracorporeal blood purification applications, including the management of cytokine storms and other inflammatory conditions associated with critical illness, cardiac surgery, trauma and sepsis. CytoSorbents also markets or develops related products, including DrugSorb-ATR, which is designed to remove certain antiplatelet and anticoagulant drugs during cardiac surgery, and VetResQ, a veterinary blood-purification product. CytoSorbents is headquartered in Princeton, New Jersey, and serves international markets through regulatory clearances, distributors and commercial partnerships. CytoSorb has been available in Europe and other markets outside the United States, while certain additional products and indications remain subject to regulatory review or clinical development. The company’s products are intended for use with established extracorporeal treatment systems in hospitals and other clinical settings.AI Generated. May Contain Errors. Read More Cytosorbents Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreCTSO MarketRank™: Cytosorbents scored higher than 48% of companies evaluated by MarketBeat, and ranked 521st out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingCytosorbents has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialCytosorbents has a consensus price target of $107.50, representing about 1,769.6% upside from its current price of $5.75.Amount of Analyst CoverageCytosorbents has only been the subject of 1 research reports in the past 90 days.Read more about Cytosorbents' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cytosorbents are expected to grow in the coming year, from ($4.40) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytosorbents is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytosorbents is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytosorbents has a P/B Ratio of 3.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cytosorbents' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted79.39% of the float of Cytosorbents has been sold short.Short Interest Ratio / Days to CoverCytosorbents has a short interest ratio ("days to cover") of 18.3, which indicates bearish sentiment.Change versus previous monthShort interest in Cytosorbents has recently increased by 6.86%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytosorbents does not currently pay a dividend.Dividend GrowthCytosorbents does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.69 News SentimentCytosorbents has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Cytosorbents this week, compared to 2 articles on an average week. Company Ownership3.5 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $92,644.00 in company stock, which represents 0.5115% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Cytosorbents insiders have bought more of their company's stock than they have sold. Specifically, they have bought $92,644.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders7.80% of the stock of Cytosorbents is held by insiders.Percentage Held by Institutions32.87% of the stock of Cytosorbents is held by institutions.Read more about Cytosorbents' insider trading history. Receive CTSO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTSO Stock News HeadlinesCytosorbents (NASDAQ:CTSO) CEO Acquires 3,774 Shares of StockSeptember 17 at 7:22 AM | insidertrades.comCytoSorbents op H.C. Wainwright conferentie: breakeven, medicijnhoopSeptember 16, 2026 | nl.investing.com“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg terminal, says a new micro cluster AI technology could render today's data centers, including Elon Musk's Colossus in Tennessee, obsolete for major breakthroughs. These next generation centers use 99 percent less space, electricity and water, yet Chaikin's research shows they could be more than a trillion times more powerful than the top data center on earth today, potentially cutting AI breakthrough timelines from five years to five days. | Chaikin Analytics (Ad)CytoSorbents出席H.C. Wainwright大会：接近盈亏平衡，新药前景可期September 16, 2026 | cn.investing.comCytosorbents consensus price target increased by 1,900% to $48.45September 15, 2026 | msn.comCytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 10, 2026 | prnewswire.comPhillip Chan Acquires 200,000 Shares of Cytosorbents (NASDAQ:CTSO) StockSeptember 10, 2026 | insidertrades.comCTSO: CytoSorbents Announces Very Positive New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on TicagrelorSeptember 3, 2026 | finance.yahoo.comSee More Headlines CTSO Stock Analysis - Frequently Asked Questions How have CTSO shares performed this year? Cytosorbents' stock was trading at $12.7840 at the beginning of the year. Since then, CTSO shares have decreased by 55.0% and is now trading at $5.75. How were Cytosorbents' earnings last quarter? Cytosorbents Corporation (NASDAQ:CTSO) posted its quarterly earnings data on Thursday, August, 6th. The medical research company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.73. The medical research company had revenue of $9.63 million for the quarter, compared to analysts' expectations of $9.39 million. Cytosorbents had a negative trailing twelve-month return on equity of 431.65% and a negative net margin of 48.94%. Read the conference call transcript. When did Cytosorbents' stock split? Shares of Cytosorbents reverse split before market open on Tuesday, September 8th 2026.A 1-20 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 7th 2026. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Cytosorbents? Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cytosorbents own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cytosorbents investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Corning (GLW), UnitedHealth Group (UNH) and Docusign (DOCU). Company Calendar Last Earnings8/06/2026Today9/19/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CTSO's financial health is in the Red zone, according to TradeSmith. CTSO has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:CTSO CIK1175151 Webwww.cytosorbents.com Phone(973) 329-8885Fax732-329-8650Employees129Year Founded2002Price Target and Rating Average Price Target for Cytosorbents$107.50 High Price Target$200.00 Low Price Target$15.00 Potential Upside/Downside+1,769.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($5.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.20 million Net Margins-48.94% Pretax Margin-50.01% Return on Equity-431.65% Return on Assets-41.94% Debt Debt-to-Equity Ratio4.70 Current Ratio0.66 Quick Ratio0.50 Sales & Book Value Annual Sales$37.06 million Price / Sales0.49 Cash FlowN/A Price / Cash FlowN/A Book Value$1.88 per share Price / Book3.06Miscellaneous Outstanding Shares3,150,000Free Float2,905,000Market Cap$18.11 million OptionableOptionable Beta1.34 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:CTSO) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | Sponsored“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytosorbents Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytosorbents With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
